Market data loadingS&P 500--NASDAQ--Data as of latest ETNo timestamp

ROCKWELL MEDICAL, INC. (RMTI) Financial Statements

ROCKWELL MEDICAL, INC. (RMTI) reported trailing twelve-month revenue of $69.4M (down 21.1% year on year) and net income of -$5.1M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: $1.5M.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

RMTIROCKWELL MEDICAL, INC.Follow RMTI — free
Drug Manufacturers - General · Healthcare
—
Price chart with a free account
Market cap
28.0M
P/E TTM
—
Dividend yield
—
52-week
—
Next earnings
12 Nov, in 19 days

Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.

LineFY2018
Dec 18
FY2019
Dec 19
FY2020
Dec 20
FY2021
Dec 21
FY2022
Dec 22
FY2023
Dec 23
FY2024
Dec 24
FY2025
Dec 25
TTM
Jun 26
Trend
Revenue63.461.362.261.972.883.6101.569.369.4
Gross profit-1.62.82.7-2.44.18.717.511.712.3
Research & development5.66.97.16.83.11.10.00.0—
Operating income-32.4-34.5-28.4-30.3-16.8-6.70.6-4.7-4.5
Pre-tax income-32.1-34.1-30.9-32.7-18.7-8.4-0.5-5.3-5.1
Income tax0.00.00.00.00.00.00.00.0—
Net income-32.1-34.1-30.9-32.7-18.7-8.4-0.5-5.3-5.1
Diluted EPS ($)-0.61-0.56-4.10-38.30-13.10-3.70-0.30-1.50-1.32
Diluted shares (mn)——7.60.91.42.33.13.6—

USD millions · SEC XBRL

ROCKWELL MEDICAL, INC. — questions

What is ROCKWELL MEDICAL, INC.'s revenue?
$69.4M over the twelve months to 2026-06-30, down 21.1% year on year, from its 10-Q and 10-K filings.
What is ROCKWELL MEDICAL, INC.'s net income?
-$5.1M over the twelve months to 2026-06-30.
What is ROCKWELL MEDICAL, INC.'s free cash flow?
$1.5M over the twelve months to 2026-06-30.
What are ROCKWELL MEDICAL, INC.'s diluted earnings per share?
$-1.32 over the twelve months to 2026-06-30.

Every figure on this page comes from ROCKWELL MEDICAL, INC.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.